乙肝患者血清ChE、HA、IL-10、IL-2的测定及其临床意义

目的:探讨血清胆碱酯酶(ChE)与肝纤维化血清标志物透明质酸(HA)、白细胞介素-10(IL-10)、白细胞介素-2(IL-2)在乙型肝炎中的诊断价值及其临床意义。方法:在BeckmanCX-20型全自动生化分析仪和爱康AE120全自动酶免仪上分别检测264例乙肝患者空腹血清ChE、HA、IL-10、IL-2活性并与52例正常患者检测结果进行比较分析。结果:与正常患者相比,各组乙肝患者血清ChE和IL-10水平显著降低,血清HA、IL-2水平显著升高,变化趋势与乙肝病情的严重程度相关。结论:血清ChE、HA、IL-10、IL-2活性活性是反映肝功能的良好指标,对于肝硬化的分级诊断也有一定的参考意义。     

HBIG—PBCA—NP对QSG、HepG及PBMC细胞增长率及毒性的影响

目的研究乙型肝炎免疫球蛋白（HBIG）聚氰基丙烯酸正丁酯纳米粒（HBIG—PBCA—NP）、PBCA—NP的体外应用安全性。方法用乳化聚合法分别制备HBIG-PBCA-NP、PBCA-NP;采用MTT比色法研究不同浓度的HBIG-PBCA-NP、PBCA—NP对外周血单核细胞（PBMC）、QSG7701细胞及HepG2.2．15细胞生长抑制作用的影响;用自动生化仪测定乳酸脱氢酶（LDH）、丙氨酸转氨酶（ALT）活性。结果按相对生长率（RGR％）,HBIG—PBCA—NP、PBCA—NP对PBMC、QSG7701细胞及HepG2．2．15细胞的毒性分级分别为0—1级,LDH与ALT释放值与HBIG、空白对照相比,差异无显著性（P〉0．01）。结论PBCA—NP属无毒级载体,HBIG—PBCA—NP具有良好的细胞生物安全性。     

HBx基因缺失型突变体HBx—d382与HBx—d431原核表达载体的构建和鉴定

目的为探讨HBx基因缺失型突变体HBx—d382和HBx—d431在临床上应用的价值,构建HBx基因缺失型突变体HBx-d382和HBx-d431原核表达载体。方法以pGM—T／HBx—d382和pGM—T／HBx-d431质粒为模板．PCR扩增含EcoRⅠ和XhoⅠ酶切位点的HBx基因片段。HBx基因PCR扩增产物与载体pET-28a（＋）经双酶切、连接,形成重组DNA后转化到大肠杆菌BL21（DE3）中,经卡那霉素筛选、酶切鉴定和DNA序列测定,筛选出重组HBx基因缺失型突变体原核表达载体。结果成功构建了重组pET-28a（＋）／HBx-d382和pET-28a（＋）HBx-d431原核表达载体,重组前后HBx基因片段序列一致。结论pET-28a（＋）／HBx-d382和pET-28a（＋）／HBx-d431原核表达载体构建成功,为HBx基因缺失型突变体HBx—d382和HBx—d431蛋白的免疫原性和临床应用的研究奠定了基础。     

乙型肝炎免疫球蛋白聚氰基丙烯酸正丁酯纳米粒抑制HBsAg、HBV DNA分泌的体外实验

Objective To investigate the inhibitive activities of hepatitis B immunoglobulin(HBIG)poly(butylcynaoacrylate)nanoparticles(HBIG-PBCA-NP)to hepatitis B surface antigen(HBsAg)and hepatitis B virus(HBV)DNA secretions using HBV infected cell model in vitro.Methods HepG 2.2.15 cells were cultured with media containing HBIG-PBCA-NP or HBIG for several days,or cultured with HBIG-PBC-NP and HBIG for 2 days and without HBIG-PBCA-NP and HBIG from day 3.The supernatants at different time points were collected for quantitative detection of HBsAg and HBV DNA.The comparisons between groups were done by variance analysis.Resalts Secretions of HBsAg and HBV DNA in supernatants of HepG2.2.15 cultured with 0.1-10.0 IU/mL of HBIG-PBCA-NP and HBIG were inhibited significantly compared with control group.HBsAg titers and HBV DNA levels in supernatants of HBIG-PBCA-NP group and HBIG group cultured with media without HBIG-PBCA-NP and HBIG kept decreasing at day 5 and 7,then rebounded at day 9 and 11.HBsAg titera in supernatants of 0.1,1.0,5.0 IU/mL HBIG-PBCA-NP group were all significantly different from those in HBIG group at day 9[(31.31±1.98)μg/L vs(40.62±2.99)μg/L,(23.79±1.31)μg/L vs(36.51±2.12)μg/L,(19.91±1.74)μg/L vs(33.03±1.65)μg/L;F=412.24,P＜0.01].Couclusion HBIG-PBCA-NP can inhibit secretions of HgsAg and HBV DNA in vitro,which is more effective than HBIG.     

乙型肝炎免疫球蛋白聚氰基丙烯酸正丁酯纳米粒抑制HBsAg、HBV DNA分泌的体外实验

Objective To investigate the inhibitive activities of hepatitis B immunoglobulin(HBIG)poly(butylcynaoacrylate)nanoparticles(HBIG-PBCA-NP)to hepatitis B surface antigen(HBsAg)and hepatitis B virus(HBV)DNA secretions using HBV infected cell model in vitro.Methods HepG 2.2.15 cells were cultured with media containing HBIG-PBCA-NP or HBIG for several days,or cultured with HBIG-PBC-NP and HBIG for 2 days and without HBIG-PBCA-NP and HBIG from day 3.The supernatants at different time points were collected for quantitative detection of HBsAg and HBV DNA.The comparisons between groups were done by variance analysis.Resalts Secretions of HBsAg and HBV DNA in supernatants of HepG2.2.15 cultured with 0.1-10.0 IU/mL of HBIG-PBCA-NP and HBIG were inhibited significantly compared with control group.HBsAg titers and HBV DNA levels in supernatants of HBIG-PBCA-NP group and HBIG group cultured with media without HBIG-PBCA-NP and HBIG kept decreasing at day 5 and 7,then rebounded at day 9 and 11.HBsAg titera in supernatants of 0.1,1.0,5.0 IU/mL HBIG-PBCA-NP group were all significantly different from those in HBIG group at day 9[(31.31±1.98)μg/L vs(40.62±2.99)μg/L,(23.79±1.31)μg/L vs(36.51±2.12)μg/L,(19.91±1.74)μg/L vs(33.03±1.65)μg/L;F=412.24,P＜0.01].Couclusion HBIG-PBCA-NP can inhibit secretions of HgsAg and HBV DNA in vitro,which is more effective than HBIG.     

胆固醇正常的急性冠脉综合征(ACS)患者高敏C反应蛋白水平与预后的相关性研究

目的 探讨胆固醇正常的急性冠脉综合征(ACS)患者高敏C反应蛋白水平(hs-CRP)浓度与临床预后的相关性.方法 对94例血清总胆固醇水平正常的ACS患者血清hs-CRP浓度结合调阅患者住院病历记录、门诊及电话随访方式进行随访、预后分析.结果 在胆固醇正常的患者中,hs-CRP升高者主要心血管不良事件(包括心源性死亡、心肌梗死、反复心绞痛发作)发生率较hs-CRP正常者低,二者对比有统计学意义(P＜0.05).结论 胆固醇正常的ACS患者hs-CRP水平的升高是预测主要心血管不良事件的独立危险因素,具有重要的临床价值.     

乙型肝炎免疫球蛋白聚氰基丙烯酸正丁酯纳米粒肝靶向性的初步研究

目的初步探讨乙型肝炎免疫球蛋白聚氰基丙烯酸正丁酯纳米粒(HBIG-PBCA-NP)的肝靶向性。方法HBIG-PBCA-NP与HepG2.2.15细胞及QSG7701细胞共孵育,透射电镜观察细胞内的纳米粒;以HBIG-PBCA-NP、PBCA-NP或HBIG尾静脉注射昆明小鼠,透射电镜观察肝细胞内的纳米粒,免疫组织化学检测肝组织HBIG的含量。结果透射电镜照片显示HepG2.2.15细胞和QSG7701细胞的胞核和胞浆内可见纳米粒,昆明种小鼠肝组织中可见大量的纳米粒;肝组织HBIG免疫组织化学结果表明相同浓度的HBIG-PBCA-NP组比HBIG组显色更明显(P<0.01)。结论HBIG-PBCA-NP较HBIG肝靶向性更好。     

呼吸道合胞病毒核酸检测阳性患儿的临床特征分析

目的分析呼吸道合胞病毒核酸(RSV-RNA)检测阳性患儿的临床特征,为临床诊断和治疗儿童呼吸道合胞病毒感染(RSV)提供依据。方法对深圳市盐田区人民医院2016-09~2017-09住院患儿中有呼吸道感染症状者进行咽拭子采样,提取RNA后用逆转录聚合酶链反应(RT-PCR)法检测RSV基因,测定病毒载量,同时抽血检测血常规和C反应蛋白(CRP)。结果 1 641例呼吸道感染患儿中RSV-RNA阳性114例,阳性率为6.95%。6个月、6个月~1岁、1岁~2岁这三组阳性率分别为14.52%、10.18%、10.96%,显著高于3岁~5岁组和≥5岁组,差异有统计学意义(P0.05);7~9月份组阳性率为15.01%,高于其他月份组,差异有统计学意义(P0.05);男童组阳性率为6.22%,女童组阳性率为7.94%,差异无统计学意义(P0.05);RSV-RNA阳性患者白细胞计数偏高占29.82%,白细胞计数正常占65.79%,白细胞计数偏低占4.39%;病毒载量在各年龄组、各性别组差异无统计学意义(P0.05);病毒载量与白细胞计数、中性粒细胞比例、淋巴细胞比例、CRP无显著相关性(P0.05)。结论 RSV-RNA检测对小儿呼吸道感染诊断具有重要价值,血常规及CRP检测对于是否病毒感染所能提供信息有限。     

日本血吸虫未成熟虫卵糖蛋白抗原生物学特性的初步分析

目的 分析日本血吸虫未成熟卵糖蛋白抗原的生物学特性。方法 利用SDS－PAEG、银染色、PAS及脂类染色对SIEA组分进行分析，并根据标准分子量迁移率Rf值，用半对数坐标纸绘图，测算各区带的分子量。结果 SIEA有10种糖蛋白分子，其分子量为101、97、91、87、77、74、66、62、56、50kDa；1条37kDa脂蛋白区带。结论 SIEA含有蛋白、糖蛋白、脂蛋白等抗原分子，可能在宿主的免疫应答中发挥不同的作用。     

乙型肝炎免疫球蛋白聚氰基丙烯酸正丁酯纳米粒抑制HBsAg、HBV DNA分泌的体外实验

Objective To investigate the inhibitive activities of hepatitis B immunoglobulin(HBIG)poly(butylcynaoacrylate)nanoparticles(HBIG-PBCA-NP)to hepatitis B surface antigen(HBsAg)and hepatitis B virus(HBV)DNA secretions using HBV infected cell model in vitro.Methods HepG 2.2.15 cells were cultured with media containing HBIG-PBCA-NP or HBIG for several days,or cultured with HBIG-PBC-NP and HBIG for 2 days and without HBIG-PBCA-NP and HBIG from day 3.The supernatants at different time points were collected for quantitative detection of HBsAg and HBV DNA.The comparisons between groups were done by variance analysis.Resalts Secretions of HBsAg and HBV DNA in supernatants of HepG2.2.15 cultured with 0.1-10.0 IU/mL of HBIG-PBCA-NP and HBIG were inhibited significantly compared with control group.HBsAg titers and HBV DNA levels in supernatants of HBIG-PBCA-NP group and HBIG group cultured with media without HBIG-PBCA-NP and HBIG kept decreasing at day 5 and 7,then rebounded at day 9 and 11.HBsAg titera in supernatants of 0.1,1.0,5.0 IU/mL HBIG-PBCA-NP group were all significantly different from those in HBIG group at day 9[(31.31±1.98)μg/L vs(40.62±2.99)μg/L,(23.79±1.31)μg/L vs(36.51±2.12)μg/L,(19.91±1.74)μg/L vs(33.03±1.65)μg/L;F=412.24,P＜0.01].Couclusion HBIG-PBCA-NP can inhibit secretions of HgsAg and HBV DNA in vitro,which is more effective than HBIG.